Hanover Portfolio Acquisitions, Inc. announced that it has concluded an international commercialization and licensing agreement with Personal Cell Sciences Corp., the developer of U Autologous(TM), a skin care suite that uses a person's own stem cells to create 'the skin care line designed and created especially for you.' The company has participated in the development of an exclusive license between Personal Cell Sciences and BALS Holdings Limited for the commercialization and distribution of Personal Cell Sciences U Autologous(TM) skin care line in Hong Kong and Macau. As a result of the transaction, the company is to receive royalty revenues from the distributor's future sales of U Autologous(TM) products in Hong Kong and Macau.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00105 USD | -4.55% |
|
+22.22% | -87.36% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
1st Jan change | Capi. | |
---|---|---|
-87.36% | 437K | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- ENDV Stock
- News Endonovo Therapeutics, Inc.
- Hanover Portfolio Acquisitions, Inc. Arranges Licensing Deal for New Stem Cell Skin Care Product